Transcatheter Embolization and Occlusion Devices – Market Insights – Europe

The European TEO device market is projected to experience modest growth over the forecast period, driven by increasing adoption of minimally invasive procedures. The trend is further supported by the introduction of innovative devices that are gaining traction due to positive clinical outcomes. As healthcare providers continue to embrace these advancements, growing confidence in novel technologies is expected to sustain steady market demand throughout the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for TEO devices in Europe from 2019 through 2034.

Companies are launching new devices as well as improved versions of existing products to remain competitive in the expanding market.

Which new devices are anticipated to enter the European market within the forecast period, and when are they expected to be launched?

Which strategies are competitors adopting to gain a competitive edge over other competitors in the TEO device market?

How has the competitive landscape changed with the emergence of new competitors and products?

How are the competitors dealing in cost-constrained markets?

DEBs and radioembolization spheres are seeing increasing adoption.

What is the adoption outlook for different embolization devices, and what factors will affect the penetration of these technologies over the forecast period?

How the rising clinical evidence is influencing the adoption of radioembolization spheres and DEBs?

How will the market growth vary across different embolization device categories?

How are radioembolization spheres being adopted by physicians in the European market? 

Emergence of evidence supporting use of embolization devices in the treatment of chronic subdural hematoma and musculoskeletal disorders will support TEO procedure volume growth.

Why liquid embolics are seeing the strongest adoption in the treatment of chronic subdural hematoma?

How will the adoption of GAE in the treatment of knee osteoarthritis vary across Europe? 

What is the reimbursement scenario for these emerging indications in Europe?